Clinical trials: in Jordan
Hypertension
Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
The aim of the observational study is to ascertain the degree of blood pressure control in the early-morning hours after 8 weeks of treatment with Telmisartan/Telmisartan+Hydrochlorothiazide and during 44 weeks of follow-up, in…
- Trial name
- NCT00946829
- Testing
- telmisartan
- Where
- 12 sites in Belgium, Canada and 10 more
- Volunteers
- 18,299 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry
The e-Ultimaster will further validate the safety and efficacy of Ultimaster DES system in unselected patients representing everyday clinical practice.
- Trial name
- e-Ultimaster (NCT02188355)
- Where
- 462 sites in Argentina, Armenia and 48 more
- Volunteers
- 37,000 people
- Sponsor
- Terumo Europe N.V.
Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for…
- Trial name
- XALIA LEA (NCT02210819)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Recommended VTE pharmacological treatments according to international guidelines
- Where
- 21 sites in Algeria, Egypt and 19 more
- Volunteers
- 1,987 people
- Sponsor
- Bayer
Acute Heart Failure
Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF
The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
- Trial name
- RELAX-AHF-ASIA (NCT02007720)
- Testing
- Serelaxin, Standard of CareTherapy
- Where
- 132 sites in China, India and 9 more
- Volunteers
- 876 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Decompensated Heart Failure
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.
- Conditions
- Heart Failure, Decompensated Heart Failure, Acute Heart Failure
- Trial name
- NCT02157506
- Testing
- CXL-1427
- Where
- 35 sites in United States, Germany and 3 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment
This clinical study will compare the equivalence of two products containing Paliperidone 100 mg in the form of a prolonged release suspension for injection in patients affected by schizophrenia who are already receiving this…
- Trial name
- NCT03425552
- Testing
- Paliperidone
- Where
- 3 sites in Jordan
- Volunteers
- 70 people
- Sponsor
- Pharmathen S.A.
Renal Cell Carcinoma
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal cell carcinoma (RCC) accounts for more than 200,000 new cases of cancer and over 100,000 cancer deaths annually in the World (Ferlay, et al., 2004).
- Trial name
- NCT01206764
- Testing
- RAD001
- Where
- 22 sites in Algeria, Egypt and 8 more
- Volunteers
- 143 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
e-BioMatrix PostMarket Registry
The purpose of this registry is to capture clinical data of the BioMatrix™ and BioMatrix Flex™ (Biolimus A9™-Eluting) stent systems in relation to safety and effectiveness.
- Trial name
- eBMX-PMR (NCT01289002)
- Where
- 69 sites in Austria, Czechia and 14 more
- Volunteers
- 5,652 people
- Sponsor
- Biosensors Europe SA
Hemophilia A
Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII
The purpose of this research study is to determine the effectiveness, safety, and pharmacokinetics (PK) of moroctocog alfa (AF-CC) in previously treated subjects, who are younger than 6 years of age, with severe or moderately…
- Trial name
- NCT00543439
- Testing
- Moroctocog alfa (AF-CC)
- Where
- 28 sites in United States, Argentina and 11 more
- Volunteers
- 66 people
- Sponsor
- Pfizer
Acute Heart Failure
Global Non-interventional Heart Failure Disease Registry
The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide.
- Trial name
- REPORT-HF (NCT02595814)
- Where
- 346 sites in United States, Algeria and 42 more
- Volunteers
- 18,805 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
Primary Objective: -To assess the change in glycosylated hemoglobin (HbA1c) in uncontrolled Type 2 diabetes patients on OAD agent in Jordan after 6 months of treatment with basal insulin (Insulin glargine).
- Trial name
- NEWLAN (NCT02606357)
- Testing
- INSULIN GLARGINE
- Where
- Jordan
- Volunteers
- 242 people
- Sponsor
- Sanofi
Advanced Breast Cancer, Breast Cancer
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
This is a study of an experimental drug (neratinib) versus a combination of drugs (lapatinib and capecitabine) in women who have erbB-2 (HER-2) positive metastatic or locally advanced breast cancer.
- Trial name
- NCT00777101
- Testing
- Neratinib, Lapatinib, Capecitabine
- Where
- 152 sites in United States, Australia and 29 more
- Volunteers
- 233 people
- Sponsor
- Puma Biotechnology, Inc.
Rheumatoid Arthritis
A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).
The study will assess the efficacy and safety of PF-06438179 and infliximab in combination with methotrexate in subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate.
- Trial name
- NCT02222493
- Testing
- PF-06438179, Infliximab
- Where
- 184 sites in United States, Australia and 26 more
- Volunteers
- 650 people
- Sponsor
- Pfizer
Complicated Urinary Tract Infection
Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.
- Trial name
- NCT00690378
- Testing
- NXL104/ceftazidime, Imipenem/Cilastatin
- Where
- 59 sites in United States, Jordan and 1 more
- Volunteers
- 137 people
- Sponsor
- Pfizer
Acute Transplant Rejection in Patients Receiving Allogeneic Renal Transplant
Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in Jordan
The purpose of this observational study was to assess the safety and efficacy of generic mycophenolate mofetil in de novo renal transplant patients in Jordan where no visits or intervention(s) additional to the daily practice…
- Trial name
- MyOra-PASS (NCT03517982)
- Testing
- Mycophenolate Mofetil
- Where
- Jordan
- Volunteers
- 12 people
- Sponsor
- Hikma Pharmaceuticals LLC
Atrial Fibrillation
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region
This international study is a prospective noninterventional observational cohort study of patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or…
- Trial name
- XANTUS-EL (NCT01800006)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 17 sites in Argentina, Azerbaijan and 15 more
- Volunteers
- 2,101 people
- Sponsor
- Bayer
Gastrointestinal Stromal Tumors
Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)
GISTs are the most common mesenchymal tumors of the gastrointestinal tract. Approximately 95% of GISTs are positive for KIT (CD117)-the receptor for stem cell factor (SCF).
- Trial name
- INV555 (NCT01172548)
- Testing
- imatinib mesylate
- Where
- 29 sites in Algeria, Egypt and 10 more
- Volunteers
- 132 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
This observational, non-interventional cohort study will evaluate predictors of response in patients with chronic hepatitis B receiving standard of care Pegasys therapy. Efficacy and safety parameters will also be evaluated.
- Trial name
- NCT01011738
- Where
- 249 sites in Austria, Bahrain and 25 more
- Volunteers
- 1,842 people
- Sponsor
- Hoffmann-La Roche
Cough
Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study
The objectives of this pivotal study are: 1. to evaluate bioavailability of an extended-release and immediate release Codeine Phosphate/Guaifenesin tablet at steady state following multiple oral administration 2.
- Trial name
- COGUSS (NCT02572375)
- Testing
- Codeine Phosphate/Guaifenesin ER Tablet, Codeine Phosphate/Guaifenesin IR Tablet
- Where
- Jordan
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Nexgen Pharma, Inc
Diabetes, Diabetes Mellitus, Type 2
Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
This study is conducted in Africa, Asia, South America and Europe. The aim of this observational study is to document the experience with the study insulins when used in routine clinical practice.
- Trial name
- A1chieve® (NCT00869908)
- Testing
- insulin aspart, insulin detemir, biphasic insulin aspart
- Where
- 22 sites in Algeria, Argentina and 20 more
- Volunteers
- 66,726 people
- Sponsor
- Novo Nordisk A/S